Abstracts
Below you can find abstracts for poster and verbal presentations delivered by our team members at conferences and other events.
To be presented at ISPOR Europe 2026
Valuation of Cost‑Effectiveness Models for Lipid‑Lowering Therapies in Atherosclerotic Cardiovascular Disease Prevention: A Systematic Literature Review
Poster Session 1 — Code EE7. Sunday 8 November 10:30–13:30. Discussion 12:30–13:30.
Authors: Ikksheta Sharma; Adam Johns; Rod S. Taylor; Ajay Malvi; Rizwan Ameen; Amatullah S. Qadeer; Oliver Darlington; Tom Ward; Alex van Doornewaard; Amy Zhou; Onivefu Odelade; Eskinder Tafesse; Juan Jose Garcia Sanchez; Andrew Briggs
Development and validation of an individual patient‑level simulation obesity model to estimate obesity progression
Poster Session 2 — Code MSR68. Monday 9 November 16:00–19:00. Discussion 18:00–19:00.
Authors: Giovanni Esposito; Laetitia Gerlier; Andrew H. Briggs; Carel W. le Roux; Andrew Walker; Ahmad Alhussein; Anindit Chhibber; Maria de Lourdes Rodriguez; Sean D. Sullivan; Anastasia Uster
Quantifying the Environmental Burden of Lipoprotein Apheresis in Homozygous Familial Hypercholesterolaemia
Poster session 2. Monday 9 November 16:00-19:00. Discussion 18:00–19:00.
Authors: Khashayar Azimpour; Laura Cornic; Patricia Causse Safar; Chiara Obici; Andrea Panico; Phil Dawson; Luke Hubbert; Cheryl Jones; Lindsay Nicholson; Andrew Briggs
Can Agentic AI Deliver HTA‑Ready Health Economic Models? Governance, Validation, and Trust
Issue panel. Tuesday 10 November 10:30–11:30.
Moderator: Andrew Briggs
Speakers: Andre Verhoek; Jag Chhatwal; Xiaoyan Wang
A Living Network Meta‑Analysis framework incorporating RWE in CLL using REAL‑SLR
Podium — Abstract 6288. “Generating Decision‑Ready Evidence for HTA and JCA” — Tuesday 10 November 10:30–11:30.
Authors: Andrew Briggs; Anna Forsythe; Saro; Mihaela
Structuring Value Elements for Cost‑Effectiveness Modelling: The STEPPS Framework Applied to Fazirsiran in AATD‑Associated Liver Disease
Poster Session 3 — Code MSR152. Tuesday 10 November 10:30–13:30. Discussion 12:30–13:30.
Authors: Andrew H. Briggs; Michael J. Lacey; Amy M. Duhig; Chitra Karki; Tami Nussbaum; Kayla Klein; Evi Germeni
Comparative Efficacy and Safety of Orforglipron vs SGLT-2 Inhibitors for the Treatment of Insufficiently Controlled Type 2 Diabetes as an Add-On to Background Therapy of 1–2 Oral Antidiabetic Drugs: A Network Meta-Analysis
Poster Session 5 — Code RWD158. Wednesday 11 November 9:00–11:30. Discussion 9:00–10:00.
Authors: Alison Davie; Tatjana Isailovic; Jennifer Alyea; Francesca Pannullo; Alice Koechlin; Andrew Briggs; Andrea Marcellusi; Christophe De Block
When the tail wags the dog – and when a population floor reins it in: extrapolation transparency across five trials
Poster Session 4 — Code EE517. Tuesday 10 November 16:00–19:00. Discussion 18:00–19:00.
Authors: Andrew Briggs; Alex Hill; Anna Forsythe
When the tail wags the dog II: how much of a mature OS benefit rests on assumption (TROPION‑Breast02)
Poster Session 3 — Code EE371. Tuesday 10 November 10:30–13:30. Discussion 12:30–13:30.
Authors: Andrew Briggs; Alex Hill; Anna Forsythe
When the tail wags the dog III: persist‑versus‑fade extrapolation & the Survival Ratio Shift (RASolute302)
Podium — Abstract 7266. “Beyond the Kaplan‑Meier Curve” — Wednesday 11 November 8:45–9:45.
Authors: Andrew Briggs; Alex Hill; Anna Forsythe
When the tail wags the dog IV: a marginal survival benefit… (PANOVA‑3)
Poster Session 2 — Code EE210. Monday 9 November 16:00–19:00. Discussion 18:00–19:00.
Authors: Andrew Briggs; Alex Hill; Anna Forsythe
When the tail wags the dog V: relative survival disciplines an implausible OS extrapolation (KEYNOTE‑905/EV‑303)
Poster Session 4 — Code MSR194. Tuesday 10 November 16:00–19:00. Discussion 18:00–19:00.
Authors: Andrew Briggs; Alex Hill; Anna Forsythe
Presented at ISPOR 2026
When the tail wags the dog: a transparency framework for survival extrapolation in oncology HTA
Presented at ISPOR 2026, Philadelphia, PA, USA.
Living Cost-Effectiveness Sequence Analysis (sequence-CEA) for Chronic Lymphocytic Leukemia (CLL): A Payer-Centric Framework for Dynamic Formulary Decision Making
Presented at ISPOR 2026, Philadelphia, PA, USA.
Evidence-Based PICO Mapping for EU Joint Clinical Assessment (JCA) Using a Real-Time AIassisted Living Systematic Literature Review (REAL-SLR): A Metastatic Breast Cancer Case Study
Presented at ISPOR 2026, Philadelphia, PA, USA.
Evidence-Based PICO Mapping for EU Joint Clinical Assessment (JCA) Using a Real-Time AI-assisted Living Systematic Literature Review (REAL-SLR): An Advanced Non-Small Cell Lung Cancer (NSCLC) Case Study
Presented at ISPOR 2026, Philadelphia, PA, USA.
Methodological Comparison of Categorized Versus Continuous Decline in Kidney Function: Insights from the CKD Care Model
Presented at ISPOR 2026, Philadelphia, PA, USA.
Assessing the Ability of the EQ-5D-5L to Capture Long-Term Health-Related Quality of Life Impacts of Hereditary Angioedema Attacks
Presented at ISPOR 2026, Philadelphia, PA, USA.
Modelling Heterogeneity Without Individual Simulation: Structural Choices And Sampling Strategies
Presented at ISPOR 2026, Philadelphia, PA, USA.
A BUDGET APART: The UK-US pharmaceutical deal and the NHS that pays for it
Presented at ISPOR 2026, Philadelphia, PA, USA.
